Evidence map›Paper›PMID 30866697›Full record

ArticleCancer biology & therapy2019

Dasatinib can enhance paclitaxel and gemcitabine inhibitory activity in human pancreatic cancer cells.

Ling Ma, Jia Wei, Gloria H Su, Jiayuh Lin

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Ling Maa Department of Clinical Laboratory, Union Hospital, Tongji Medical College , Huazhong University of Science and Technology , Wuhan , China.
Jia Weib Department of Biochemistry and Molecular Biology, School of Medicine , University of Maryland , Baltimore , MD , USA.
Gloria H Suc Department of Pathology and Cell Biology , Columbia University Medical Center , New York , NY , USA.
Jiayuh Linb Department of Biochemistry and Molecular Biology, School of Medicine , University of Maryland , Baltimore , MD , USA.
University of Maryland, Baltimore · USColumbia University Irving Medical Center · US

Funding

The Development And Progression Of IPMN To PDA In The Context Of Inactivated Activin SignalingR01CA217207 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SU, GLORIA HUEI-TING · 2017 to 2021
$2.4M
The role of wild-type KRAS in the context of tumor profession and metastasisR01CA178445 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SU, GLORIA HUEI-TING · 2015 to 2019
$2.2M
NCI NIH HHS R01 CA178445NCI NIH HHS R01 CA217207
6 · The paper itself

Abstract

SRC and its activated form, phospho-SRC (pSRC), are aberrantly activated in pancreatic cancer and SRC represents a potential target for pancreatic cancer therapy. In this paper, we examined the inhibitory effect of dasatinib, a potent SRC inhibitor in combination with paclitaxel or gemcitabine on human and murine pancreatic cancer cell lines. The results showed that p-SRC can be highly expressed in most human and mouse pancreatic cancer cell lines compared with normal human cell lines and can be induced by paclitaxel or gemcitabine in HPAC cells. Dasatinib can enhance the efficacy of paclitaxel or gemcitabine by reducing the cell viability and inhibiting the cell proliferation. Dasatinib with paclitaxel combination exhibits statistically greater inhibition of the cell migration ability than single agent alone, paclitaxel with gemcitabine or FOLFIRINOX (combination of fluorouracil, leucovorin, irinotecan, and oxaliplatin) in HAPC, PANC-1, and BXPC-3 human pancreatic cancer cell lines as well as 8-285 APR and 8-365 APR mouse pancreatic cancer cell lines. In addition, dasatinib with gemcitabine combination also showed statistically greater inhibition of cell migration than single agent alone, paclitaxel with gemcitabine, or FOLFIRINOX in HAPC, PANC-1 and 8-285 APR cells. The combination of dasatinib with paclitaxel or gemcitabine also showed greater inhibition of the colony formation ability of pancreatic cancer cells compared with single-agent monotherapy or FOLFIRINOX. Dasatinib with paclitaxel or gemcitabine combination also inhibits p-SRC, p-STAT3, p-AKT, and/or p-ERK in these pancreatic cancer cells. Therefore, our results support that combined dasatinib and paclitaxel or gemcitabine therapy may be a viable therapeutic approach for human pancreatic cancer.

Indexed as

Antineoplastic AgentsApoptosisCell Line, TumorCell ProliferationCell SurvivalDasatinibDeoxycytidineDrug SynergismGemcitabineHumansPaclitaxelPancreatic NeoplasmsSignal TransductionSTAT3 Transcription FactorAntineoplastic AgentsDasatinibDeoxycytidineGemcitabinePaclitaxelSTAT3 protein, humanSTAT3 Transcription FactordasatinibgemcitabinepaclitaxelPancreatic cancerp-SRC

Identifiers

PMID30866697
PMCPMC6606004
OpenAlexW2921948547

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.